98 related articles for article (PubMed ID: 32928086)
1.
Khan PM; Kumar V; Roy K
Comb Chem High Throughput Screen; 2021; 24(8):1281-1299. PubMed ID: 32928086
[TBL] [Abstract][Full Text] [Related]
2. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
Kumar V; Roy K
SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
[TBL] [Abstract][Full Text] [Related]
3. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
Ishola AA; Adedirin O; Joshi T; Chandra S
Comput Biol Med; 2021 Jul; 134():104483. PubMed ID: 34020129
[TBL] [Abstract][Full Text] [Related]
4. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
Amin SA; Ghosh K; Gayen S; Jha T
J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study.
Kumar V; Kar S; De P; Roy K; Leszczynski J
SAR QSAR Environ Res; 2022 May; 33(5):357-386. PubMed ID: 35380087
[TBL] [Abstract][Full Text] [Related]
6. QSAR, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective benzotriazole-based SARS-CoV 3CL protease inhibitors.
D'Souza S; Balaji S; K V P
J Biomol Struct Dyn; 2022; 40(24):14247-14261. PubMed ID: 34877897
[TBL] [Abstract][Full Text] [Related]
7.
De P; Bhayye S; Kumar V; Roy K
J Biomol Struct Dyn; 2022 Feb; 40(3):1010-1036. PubMed ID: 32954984
[TBL] [Abstract][Full Text] [Related]
8. Development of a deep learning-based quantitative structure-activity relationship model to identify potential inhibitors against the 3C-like protease of SARS-CoV-2.
Kumari M; Subbarao N
Future Med Chem; 2022 Nov; 14(21):1541-1559. PubMed ID: 36177879
[No Abstract] [Full Text] [Related]
9.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
10. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
11. Suggestion of active 3-chymotrypsin like protease (3CL
Mozafari Z; Chamjangali MA; Arashi M; Goudarzi N
SAR QSAR Environ Res; 2021 Nov; 32(11):863-888. PubMed ID: 34634208
[TBL] [Abstract][Full Text] [Related]
12. QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL
Jawarkar RD; Bakal RL; Zaki MEA; Al-Hussain S; Ghosh A; Gandhi A; Mukerjee N; Samad A; Masand VH; Lewaa I
Arab J Chem; 2022 Jan; 15(1):103499. PubMed ID: 34909066
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV M
Toropov AA; Toropova AP; Veselinović AM; Leszczynska D; Leszczynski J
J Biomol Struct Dyn; 2022 Feb; 40(2):780-786. PubMed ID: 32907512
[TBL] [Abstract][Full Text] [Related]
14. In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening.
Ghaleb A; Aouidate A; Ayouchia HBE; Aarjane M; Anane H; Stiriba SE
J Biomol Struct Dyn; 2022 Jan; 40(1):143-153. PubMed ID: 32799761
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and
Glaab E; Manoharan GB; Abankwa D
J Chem Inf Model; 2021 Aug; 61(8):4082-4096. PubMed ID: 34348021
[TBL] [Abstract][Full Text] [Related]
16. Deep learning model for virtual screening of novel 3C-like protease enzyme inhibitors against SARS coronavirus diseases.
Kumari M; Subbarao N
Comput Biol Med; 2021 May; 132():104317. PubMed ID: 33721736
[TBL] [Abstract][Full Text] [Related]
17. Computational modeling of the bat HKU4 coronavirus 3CL
Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
[TBL] [Abstract][Full Text] [Related]
18. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.
Rehman MT; AlAjmi MF; Hussain A
Curr Pharm Des; 2021; 27(33):3577-3589. PubMed ID: 33200697
[TBL] [Abstract][Full Text] [Related]
19. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening of approved clinic drugs with main protease (3CL
Wang Q; Zhao Y; Chen X; Hong A
J Biomol Struct Dyn; 2022 Feb; 40(2):685-695. PubMed ID: 32909528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
